Literature DB >> 7698346

An extracellular residue determines the agonist specificity of V2 vasopressin receptors.

E Ufer1, R Postina, V Gorbulev, F Fahrenholz.   

Abstract

The specific V2 agonist 1-deamino [8-D-arginine]-vasopressin (dDAVP), used for treatment of central diabetes insipidus, binds to vasopressin V2 receptors from human, bovine and rat kidney with an affinity that is similar to that of the natural hormone vasopressin. In contrast, the V1 receptors and the porcine V2 receptor do not tolerate a D-arginine in position 8 of vasopressin. By site directed mutagenesis of the cloned bovine and porcine V2 receptors we identified a residue (Asp-103) in the first extracellular loop of vasopressin receptors which is responsible for high affinity binding of dDAVP.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7698346     DOI: 10.1016/0014-5793(95)00150-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Mutational analysis and molecular modeling of the nonapeptide hormone binding domains of the [Arg8]vasotocin receptor.

Authors:  H Hausmann; A Richters; H J Kreienkamp; W Meyerhof; H Mattes; K Lederis; H Zwiers; D Richter
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Identification of the glycosylation sites utilized on the V1a vasopressin receptor and assessment of their role in receptor signalling and expression.

Authors:  S R Hawtin; A R Davies; G Matthews; M Wheatley
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

3.  Visualizing microtubule-dependent vasopressin type 2 receptor trafficking using a new high-affinity fluorescent vasopressin ligand.

Authors:  Sylvia Chen; Matthew J Webber; Jean-Pierre Vilardaga; Ashok Khatri; Dennis Brown; Dennis A Ausiello; Herbert Y Lin; Richard Bouley
Journal:  Endocrinology       Date:  2011-08-09       Impact factor: 4.736

4.  Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

Authors:  C Serradeil-Le Gal; C Lacour; G Valette; G Garcia; L Foulon; G Galindo; L Bankir; B Pouzet; G Guillon; C Barberis; D Chicot; S Jard; P Vilain; C Garcia; E Marty; D Raufaste; G Brossard; D Nisato; J P Maffrand; G Le Fur
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

Review 5.  Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies.

Authors:  B Mouillac; M Manning; T Durroux
Journal:  Mini Rev Med Chem       Date:  2008-09       Impact factor: 3.862

6.  Molecular modeling of the human vasopressin V2 receptor/agonist complex.

Authors:  C Czaplewski; R Kaźmierkiewicz; J Ciarkowski
Journal:  J Comput Aided Mol Des       Date:  1998-05       Impact factor: 3.686

7.  Molecular dynamics study of 4-OH-phenylacetyl- D-Y(Me)FQNRPR-NH2 selectivity to V1a receptor.

Authors:  Artur Giełdoń; Rajmund Kaźmierkiewicz; Rafał Slusarz; Marta Pasenkiewicz-Gierula; Jerzy Ciarkowski
Journal:  J Mol Model       Date:  2003-10-07       Impact factor: 1.810

8.  Molecular evolution of the neuropeptide S receptor.

Authors:  Thejkiran Pitti; Narayanan Manoj
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

9.  Induction of RAGE shedding by activation of G protein-coupled receptors.

Authors:  Verena V Metz; Elzbieta Kojro; Dorothea Rat; Rolf Postina
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

10.  Study of V2 vasopressin receptor hormone binding site using in silico methods.

Authors:  Yeganeh Sebti; Soroush Sardari; Hamid Mir Mohammad Sadeghi; Mohammad Hossein Ghahremani; Giulio Innamorati
Journal:  Res Pharm Sci       Date:  2015 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.